biowa,
and CNSI,LIPO,GNLB,CEPH,REGN...
I'm sure that many people are thinking about these and other companies that have served up fiascoes during the year. No matter how it's administered, it's a bitter pill to take. Those that can't stop thinking about those failures will probably opt for the sidelines.
The stock price can gyrate,but until I learn of something that substantially alters the outlook,I'm staying put,for the quality of the science and technology must eventually win out. How to characterize that science? Heretofore,by all accounts,it has been exemplary. I can't say the same for some of the aforementioned companies,as some people whose judgment I respect had large short positions in them. ABTI has shown how PGG-glucan effects an immunostimulatory response and demonstrated the effectiveness of that response in the two major studies done thus far. This, despite the presence of factors that led some researchers to believe that the studies were biased against the potential efficacy of PGG-glucan. (increased number of diabetics,higher percentage of clean-contaminated cases and an older average age for patients that received PGG-glucan in the Phase 1-2 trial and the presence of pre-existing infections in the second Phase 2) It's possible that since the Phase 3 trial will exclude patients exhibiting prior infection and will include a much broader patient population, that the results will equal or surpass those obtained in the prior studies. Of course,the results might not be up to the prior data. If they're not significantly worse than before,PGG-glucan will likely merit approval. Here's hoping ABTI will turn the tide in the sector. |
